![](/img/cover-not-exists.png)
Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
Chen, Jun, Hu, Gaoyun, Chen, Zhuo, Wan, Xiaomin, Tan, Chongqing, Zeng, Xiaohui, Cheng, ZenengLanguage:
english
Journal:
Clinical Drug Investigation
DOI:
10.1007/s40261-019-00820-6
Date:
June, 2019
File:
PDF, 1.15 MB
english, 2019